Association between Chinese Medicine Therapy and Survival Outcomes in Postoperative Patients with NSCLC: A Multicenter, Prospective, Cohort Study

HFCAS OpenIR

	Association between Chinese Medicine Therapy and Survival Outcomes in Postoperative Patients with NSCLC: A Multicenter, Prospective, Cohort Study
其他题名	Association between Chinese Medicine Therapy and Survival Outcomes in Postoperative Patients with NSCLC: A Multicenter, Prospective, Cohort Study
	Wang Xueqian 1; Zhang Ying 1; Hou Wei 1; Wang Yingtian 1; Zheng Jiabin 1; Li Jie 1; Lin Lizhu 2; Jiang Yilan 3; Wang Shenyu 4; Xie Ying 4; Zhang Hongliang 5; Shu Qijin 6; Li Ping 7; Wang Wei4 ; You Jianliang 8; Li Ge9 ; Liu Jie 1; Fan Huiting 1; Zhang Meiying 1; Lin Hongsheng 1
	2019
发表期刊	CHINESE JOURNAL OF INTEGRATIVE MEDICINE
ISSN	1672-0415
摘要	Objective: To evaluate the association between Chinese medicine (CM) therapy and disease-free survival (DFS) outcomes in postoperative patients with non-small cell lung cancer (NSCLC). Methods: This multiple-center prospective cohort study was conducted in 13 medical centers in China. Patients with stage I, II or IIIA NSCLC who had undergone radical resection and received conventional postoperative treatment according to the National Comprehensive Cancer Network (NCCN) guidelines were recruited. The recruited patients were divided into a CM treatment group and a control group according to their wishes. Patients in the CM treatment group received continuous CM therapy for more than 6 months or until disease progression. Patients in the control group received CM therapy for less than 1 month. Follow-up was conducted over 3 years. The primary outcome was DFS, with recurrence/metastasis rates as a secondary outcome. Results: Between May 2013 and August 2016, 503 patients were enrolled into the cohort; 266 were classified in the CM treatment group and 237 in the control group. Adjusting for covariates, high exposure to CM was associated with better DFS hazard ratio (HR) = 0.417, 95% confidential interval (CI): 0.307-0.567). A longer duration of CM therapy (6-12 months, 12-18 months, >24 months) was associated with lower recurrence and metastasis rates (HR = 0.225, 0.119 and 0.083, respectively). In a subgroup exploratory analysis, CM therapy was also a protective factor of cancer recurrence and metastasis in both stage II-IIIA (HR=0.50, 95% CI: 0.37-0.67) and stage IIIA NSCLC postoperative patients (HR = 0.48, 95% CI: 0.33-0.71), DFS was even longer among CM treatment group patients. Conclusions: Longer duration of CM therapy could be considered a protective factor of cancer recurrence and metastasis. CM treatment is associated with improving survival outcomes of postoperative NSCLC patients in China.
其他摘要	Objective: To evaluate the association between Chinese medicine(CM) therapy and disease-free survival(DFS) outcomes in postoperative patients with non-small cell lung cancer(NSCLC). Methods: This multiple-center prospective cohort study was conducted in 13 medical centers in China. Patients with stage Ⅰ, Ⅱ, or ⅢA NSCLC who had undergone radical resection and received conventional postoperative treatment according to the National Comprehensive Cancer Network(NCCN) guidelines were recruited. The recruited patients were divided into a CM treatment group and a control group according to their wishes. Patients in the CM treatment group received continuous CM therapy for more than 6 months or until disease progression. Patients in the control group received CM therapy for less than 1 month. Follow-up was conducted over 3 years. The primary outcome was DFS, with recurrence/metastasis rates as a secondary outcome. Results: Between May 2013 and August 2016, 503 patients were enrolled into the cohort; 266 were classified in the CM treatment group and 237 in the control group. Adjusting for covariates, high exposure to CM was associated with better DFS hazard ratio(HR) = 0.417, 95% confidential interval(CI): 0.307–0.567). A longer duration of CM therapy(6–12 months, 12–18 months, >24 months) was associated with lower recurrence and metastasis rates(HR = 0.225, 0.119 and 0.083, respectively). In a subgroup exploratory analysis, CM therapy was also a protective factor of cancer recurrence and metastasis in both stage Ⅱ–ⅢA(HR=0.50, 95% CI: 0.37–0.67) and stage ⅢA NSCLC postoperative patients(HR = 0.48, 95% CI: 0.33–0.71), DFS was even longer among CM treatment group patients. Conclusions: Longer duration of CM therapy could be considered a protective factor of cancer recurrence and metastasis. CM treatment is associated with improving survival outcomes of postoperative NSCLC patients in China.(Registration No. ChiCTR-OOC-14005398).
关键词	CELL LUNG-CANCER ADJUVANT CHEMOTHERAPY Chinese medicine non-small cell lung cancer postoperative care cohort study disease-free survival
收录类别	CSCD
语种	英语
资助项目	[Special Funded Projects of the TCM Industry] ; [National Natural Science Foundation of China] ; [Beijing Natural Science Fund]
CSCD记录号	CSCD:6595063
引用统计
文献类型	期刊论文
条目标识符	http://ir.hfcas.ac.cn:8080/handle/334002/46188
专题	中国科学院合肥物质科学研究院
作者单位	1.中国科学院 2.广州大学 3.Hunan Acad Tradit Chinese Med, Affiliated Hosp, Department Oncol, Changsha 410000, Peoples R China Affiliated Hosp Department Oncol 4.中国科学院合肥物质科学研究院肿瘤医院 5.Xinjiang Uygur Autonomous Reg Tradit Chinese Med, Department Oncol, Urumqi 830000, Peoples R China Department Oncol 6.Zhejiang Prov Tradit Chinese Med Hosp, Department Oncol, Hangzhou 310000, Peoples R China Department Oncol 7.Anhui Prov Hosp, Oncol Department Tradit Chinese Med, Hefei 230000, Peoples R China Oncol Department Tradit Chinese Med 8.Wuxi Hosp Tradit Chinese Med, Department Oncol, Wuxi 214000, Jiangsu, Peoples R China Department Oncol 9.Dalian Hosp Tradit Chinese Med, Department Oncol, Dalian 116000, Liaoning, Peoples R China Department Oncol
推荐引用方式 GB/T 7714	Wang Xueqian,Zhang Ying,Hou Wei,et al. Association between Chinese Medicine Therapy and Survival Outcomes in Postoperative Patients with NSCLC: A Multicenter, Prospective, Cohort Study[J]. CHINESE JOURNAL OF INTEGRATIVE MEDICINE,2019,25.
APA	Wang Xueqian.,Zhang Ying.,Hou Wei.,Wang Yingtian.,Zheng Jiabin.,...&Lin Hongsheng.(2019).Association between Chinese Medicine Therapy and Survival Outcomes in Postoperative Patients with NSCLC: A Multicenter, Prospective, Cohort Study.CHINESE JOURNAL OF INTEGRATIVE MEDICINE,25.
MLA	Wang Xueqian,et al."Association between Chinese Medicine Therapy and Survival Outcomes in Postoperative Patients with NSCLC: A Multicenter, Prospective, Cohort Study".CHINESE JOURNAL OF INTEGRATIVE MEDICINE 25(2019).